bluebird bio Inc (NASDAQ:BLUE) just announced Phase 1 results of bb2121, the BCMA CAR-T therapy, in patients with relapsed /refractory multiple myeloma that …
Merrill Lynch dives into the biotech world as analysts explore positive catalysts for giants Gilead Sciences, Inc. (NASDAQ:GILD) and Pfizer Inc.
Gilead Sciences, Inc. (NASDAQ:GILD) announced yesterday that the firm will be terminating its Phase 2/3 clinical study evaluating its pipeline drug GS-5745, an …
Merrill Lynch’s healthcare analyst Ying Huang weighed in on Intercept Pharmaceuticals Inc (NASDAQ:ICPT), after the FDA advisory committee unanimously recommended approval of the company’s liver drug. The …
Gilead Sciences (NASDAQ: GILD) is a Foster City, California based bio-pharmaceutical company that discovers, develops and commercializes therapeutics for unmet medical areas in need. …
